To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052)

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To collect clinical response data with the use of ertapenem in approved indications.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Anti-Infective Agents; Ertapenem

Criteria

Inclusion Criteria:

• Male or female patients, 20 years of age or older

• Patients did not receive any systemic antibiotic before enrollment, or patients with failed clinical response (no improvement on symptoms or laboratory data) through previous antibiotic treatment

• Patients who required therapy prior to identification of cause of infection

Exclusion Criteria:

• Patient has a concomitant infection that may interfere with the evaluation of the response to ertapenem

• Patient has an apache ii > 30.

• Patient has an infection caused by pathogens resistant to ertapenem

• Patients with known allergy to ertapenem or other drugs in the same carbapenem class, beta - lactams, lidocaine or local anesthetics of the amide type

• The patient requires antibiotics other than ertapenem (such as: glycopeptides, macrolides or antifungal agents)